The importance of polymorphisms of the ABCB1 and CYP3A5 genes in predicting the efficacy and safety of amlodipine in patients with arterial hypertension of 1-2 degree

Purpose. Increase of efficacy and safety of pharmacotherapy of AH 1-2 degree for personalization of choice of amlodipine dosage regimens based on genotyping according to ABCB1, CYP3A5. Materials and methods. Antihypertensive efficacy and tolerability of amlodipine was evaluated in 100 patients with AH 1-2 degree at the age of 49 to 67 years (compare age 53.9-10.9), depending on the genotypes of the ABCB1 and CYP3A5 genes. Results. Detection of the TT genotype by the polymorphic marker C3435T of the ABCB1 gene predicts an excellent antihypertensive efficacy of amlodipine (sensitivity 36.8%, specificity 90.3%), and therefore its initial dose may be 5 mg/day; detection of the HS genotype - lower antihypertensive efficacy (sensitivity 32.7%, specificity 86.6%), and therefore it is advisable to prescribe amlodipine at a dose of 10 mg/day. The detection of the GG genotype by the polymorphic marker A6986G of the CYP3A5 gene is associated with a higher risk of developing NDP (sensitivity 28.8%, specificity 92.7%), which makes undesirable growth to amlodipine from 5 to 10 mg. Occlusion. Carrying of different genotypes ABCB1 on polymorphic marker C3435T is associated with indicators of antihypertensive efficacy of amlodipine, and carriage of various CYP3A5 genotypes by polymorphic marker A6986G - with safety parameters for long-term use.

arterial hypertension, amlodipine, efficacy, safety, pharmacogenetics, ABCB1 gene, CYP3A5 gene, gene polymorphism